文献速递泌尿生殖与妇科肿瘤放疗

表观扩散系数对前列腺癌根治性放疗后早期预测治疗反应的影响

The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients.
PubMed 文献 · Radiother Oncol · 2023-04-20

该回顾性研究评估229例低中危前列腺癌患者根治性放疗(未联合雄激素剥夺治疗)后ADC与PSA的早期变化,中位随访80.8个月,5年FFBF与PFS分别为95.9%与89.3%;复发者治疗后ADC显著低于无复发者,低ADC、GS 4+3及中危疾病为FFBF独立不良预测因素,低治疗后ADC与GS 4+3为PFS显著预后因素。

要点

  • 229例低中危前列腺癌根治性放疗后中位4.1个月行DW-MRI,中位随访80.8个月。
  • 复发者治疗后ADC 0.94±0.07 vs 无复发者1.10±0.20×10-3 mm2/sec,p<0.001。
  • 肿瘤ADC≤0.96×10-3 mm2/sec者5年FFBF 85.5% vs >0.96者100%,p<0.001。

核心结论

  • 作者认为治疗后肿瘤ADC值可用于前列腺癌根治性放疗后的早期治疗反应评估。

研究设计与样本

  • 回顾性评估229例低危和中危前列腺癌患者的临床数据与ADC参数。
  • 患者接受根治性放疗且未行雄激素剥夺治疗,治疗后中位4.1个月行DW-MRI。
  • 采用单因素和多因素分析评估预测无生化失败生存(FFBF)与无进展生存(PFS)的预后因素。

主要发现

  • 中位随访80.8个月,5年FFBF为95.9%,5年PFS为89.3%。
  • 11例(4.8%)出现PSA复发,复发中位时间为放疗完成后34.4个月。
  • 复发者治疗后ADC为0.94±0.07×10-3 mm2/sec,无复发者为1.10±0.20×10-3 mm2/sec,差异有统计学意义(p<0.001)。
  • GS 6及低危患者治疗后肿瘤ADC和PSA水平显著高于GS 7及中危患者。
  • 肿瘤ADC≤0.96×10-3 mm2/sec者5年FFBF为85.5%,显著低于ADC>0.96×10-3 mm2/sec者的100%(p<0.001)。

关键数值与推荐

  • 肿瘤ADC阈值0.96×10-3 mm2/sec:≤该值者5年FFBF 85.5% vs >该值者100%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed early changes in apparent diffusion coefficient (ADC) and serum prostate specific antigen (PSA) values after definitive radiotherapy (RT) without androgen deprivation treatment in low- and intermediate-risk prostate cancer (PC) patients. MATERIALS AND METHODS: The clinical data and ADC parameters of 229 PC patients were retrospectively evaluated. Pre-treatment and post-treatment serum PSA and primary tumor ADC values were calculated. Post-treatment DW-MRI was performed median 4.1 months after completion of definitive RT. The prognostic factors predicting freedom from biochemical failure (FFBF) and progression-free survival (PFS) were analyzed using univariable and multivariable analyses. RESULTS: With a median follow-up time of 80.8 months, the 5-year FFBF and PFS rates were 95.9% and 89.3%, respectively. Eleven patients (4.8%) had PSA relapse, with a median of 34.4 months after the completion of RT. A statistically significant difference in post-treatment ADC values was noted between patients with and without recurrence (0.94 ± 0.07 vs. 1.10 ± 0.20 × 10-3 mm2/sec; p< 0.001). Patients with a Gleason score (GS) of 6 and low-risk disease had significantly higher post-treatment tumor ADC and PSA levels than patients with a GS of 7 and intermediate-risk disease. The 5-year FFBF rate in patients with tumor ADC ≤ 0.96 × 10-3 mm2/sec was significantly lower than patients with tumor ADC > 0.96 × 10-3 mm2/sec (85.5% vs. 100; p< 0.001). In the multivariable analysis, a lower ADC value, GS 4 + 3 and intermediate-risk disease were independent predictors of worse FFBF. In the multivariate analysis, a lower post-treatment ADC value and a GS of 4 + 3 were significant prognostic factors for a lower PFS. CONCLUSION: These findings suggest that the post-treatment tumor ADC value could be used for early treatment response evaluation after definitive RT in PC patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Onal C, Erbay G, Oymak E, et al. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients. Radiother Oncol. 2023. PMID: 37084886. doi:10.1016/j.radonc.2023.109677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。